Nichido
Nuchido TIME+™ NAD Supplement (90 Days)
Nuchido TIME+™ NAD Supplement (90 Days)
无法加载取货服务可用情况
Product Overview
Nuchido TIME+ is manufactured by Nuchido Laboratories Ltd (United Kingdom) and represents a third-generation NAD+ intervention. Rather than supplying NAD+ precursors alone (e.g. nicotinamide riboside or nicotinamide mononucleotide), the formulation applies a systems-biology approach that simultaneously addresses the three principal mechanisms of age-associated NAD+ decline: insufficient precursor availability, impaired NAD+ salvage pathway activity (specifically reduced NAMPT enzyme expression), and excessive NAD+ consumption by chronic inflammatory pathways and CD38 activity. This multi-target architecture is the basis on which Nuchido distinguishes its product from single-precursor competitors.
The 90-day pack contains three monthly bottles supplying a continuous daily dose for adults aged 30 and above seeking to maintain or restore cellular NAD+ levels. The clinical evidence base includes a randomised, double-blind, crossover human trial (Dollerup et al., npj Aging, 2024) in 26 participants aged 20-80 years, demonstrating significant elevation of whole-blood NAD+, increased SIRT1 and NAMPT expression in peripheral blood mononuclear cells, reduction in plasma pro-inflammatory cytokines including IL-2, and a measurable decrease in glycated serum protein, indicating downstream metabolic benefit.
Specifications
| Manufacturer | Nuchido Laboratories Ltd, United Kingdom |
|---|---|
| Pack Size | 90-day supply (3 x 30-day bottles, monthly subscription or one-off purchase) |
| Daily Dose | 2 capsules with breakfast |
| Active Ingredients | Nicotinamide, Parsley leaf extract (apigenin source), Sophora japonica extract (quercetin, rutin, troxerutin), Green tea extract (EGCG), Alpha Lipoic Acid, Vitamin C (ascorbic acid), Zinc, Black Pepper extract (piperine, bioavailability enhancer) |
| Mechanism | Multi-target NAD+ system support: precursor supply, NAMPT salvage upregulation, CD38 inhibition, anti-inflammatory NAD+ preservation |
| Clinical Evidence | Randomised double-blind crossover human trial: 242% mean increase in cellular NAD+ at 16 days (Dollerup et al., npj Aging 2024, doi:10.1038/s41514-023-00134-0) |
| Capsule Type | Vegan; gluten-free; non-GMO |
| Excludes | Wheat, dairy, soy, artificial colours and preservatives |
| Manufacturing Standards | UK GMP-certified facility; ISO 22000 food safety; ISO 9001 quality management |
| Regulatory | UK MHRA food supplement compliance; EU EFSA novel food assessment passed; HSA Singapore health supplement notification framework |
| Storage | Store below 25°C in a dry place, away from direct sunlight |
| Shelf Life | 24 months from manufacture; refer to bottle for batch-specific expiry |
Clinical Indications
- Adults aged 30 and above pursuing structured cellular ageing, healthspan, or longevity protocols
- Patients with measured low cellular NAD+ via metabolomic testing (e.g. Jinfiniti or comparable assay)
- Adjunct nutritional support for metabolic syndrome, insulin resistance, or pre-diabetes given documented reduction in glycated serum protein
- Recovery support after acute illness, antibiotic courses, or sustained inflammatory states where NAD+ depletion is anticipated
- Patients on chronic medications associated with mitochondrial stress (statins, metformin) seeking to restore cellular bioenergetics
- Individuals integrating NAD+ optimisation into a broader regimen of resistance training, time-restricted eating, and sleep optimisation
Frequently Asked Questions
How does Nuchido TIME+ differ from NMN or NR supplements?
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are direct NAD+ precursors that supply substrate for NAD+ synthesis. Nuchido TIME+ supplies a precursor (nicotinamide) plus a stack of bioactives that upregulates the NAMPT salvage enzyme, inhibits CD38-mediated NAD+ degradation, and reduces inflammation-driven NAD+ consumption. The published clinical evidence reporting a 242 percent NAD+ increase at 16 days is among the larger effect sizes documented for any oral NAD+ intervention to date.
Is Nuchido TIME+ supported by peer-reviewed evidence?
Yes. The pivotal clinical trial (Dollerup et al., npj Aging, Nature Portfolio, 2024) was a double-blind, randomised, placebo-controlled crossover study. The methodology and outcomes have been peer-reviewed and indexed on PubMed. Buyers should review the open-access publication directly and discuss the data with a qualified healthcare provider familiar with longevity medicine.
What is the safety profile?
In the 26-participant clinical trial, very few adverse effects were reported: two participants noted disturbed sleep when taking Nuchido TIME+ and one reported transient stomach irritation. The supplement is not recommended during pregnancy or lactation, in children under 18, or in patients on chemotherapy, immunosuppressive therapy, or strong CYP3A4-modulating drugs without prior physician review. Patients with known allergy to soy, parsley, or sophora-derived flavonoids should avoid the product.
How is the product regulated for sale in Singapore?
Nuchido TIME+ is supplied as a health supplement under the Singapore HSA framework, which does not require pre-market product registration but mandates compliance with the Health Products Act and labelling, ingredient permissibility, and contaminant limits. EMIS+ sources stock through the Nuchido authorised channel, ensuring batch documentation, certificate of analysis availability, and cold-chain integrity from manufacture to delivery.
Why purchase the 90-day pack rather than the 30-day pack?
The clinical trial used 28 days of continuous daily dosing to establish baseline NAD+ elevation; sustained cellular and inflammatory adaptations are reported with longer regimens. The 90-day pack ensures uninterrupted dosing across a full quarterly cycle, supports compliance, and offers improved per-day economics for patients committing to a structured longevity protocol.
分享
